中材科技(002080.SZ):擬斥9.65億元在泰安市投建一條年產9萬噸新一代高模高強玻璃纖維生產線
格隆匯4月21日丨中材科技(002080.SZ)宣佈,公司第六屆董事會第二十四次臨時會議審議通過了《關於泰山玻璃纖維有限公司建設年產9萬噸新一代高模高強玻璃纖維生產線的議案》。公司全資子公司泰山玻璃纖維有限公司(簡稱“泰山玻纖”)擬在山東省泰安市投資約9.65億元建設一條年產9萬噸新一代高模高強玻璃纖維生產線。
公司表示,該項目符合國家實現低碳發展的需求和國內外複合材料市場需求,項目建設將進一步優化泰山玻纖的產品結構,拓寬產品市場範圍,有利於公司玻璃纖維產業高端化發展,持續增強核心競爭力,對實現產業持續健康發展具有重要意義和示範效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.